Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital

Revista Brasileira de Hematologia e Hemoterapia

Samuel Roosevelt Campos Dos Reis¹  Acy Telles De Souza Quixada¹  Sammara Tavares Nunes¹  Danielle Maria Camelo Cid¹  Jacqueline Holanda De Souza¹  Clara Maria Bastos Eloy Da Costa¹  Carolina Bizelli Silveira¹  David Antonio Camelo Cid¹  Mariana Fatima Cabral De Oliveira¹ 

关键词: Leukemia;    myelogenous;    chronic;    BCR-ABL positive/drug therapy;    Piperazines/therapeutic use;    Medication adherence;    Fusion Proteins;    bcr-abl/genetic;    Treatment outcome;   

DOI  :  10.5581/1516-8484.20130053

来源: SciELO

【 摘 要 】

Objetive: The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia.Methods: A retrospective review was performed of 100 non-electronic records of patients with Ph+ chronic myeloid leukemia treated with imatinib mesylate. The study period was from January 2001 to January2011. Data were analyzed by Chi-Square and Correspondence analysis using the Statistical Analysis System software package.Results: At the beginning of treatment 41% of patients were in advanced stages of the disease. The unavailability of the drug (44.8%) and myelotoxicity (25.7%) were the most frequent reasons for interruption. The adherence rate was < 90% in 47% of the cases. The low adherence influenced the cytogenetic response (p-value = 0.020) and molecular response (p-value = 0.001). Very high adherence (> 95%) induced complete cytogenetic response, major cytogenetic response and major molecular response.Conclusion: The population of this study obtained lower-than-expected therapeutic responses compared to other studies.

【 授权许可】

CC BY-NC-ND   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License